Pfizer Inc. to Post Q3 2025 Earnings of $0.72 Per Share, Zacks Research Forecasts (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) – Investment analysts at Zacks Research decreased their Q3 2025 earnings per share (EPS) estimates for Pfizer in a report issued on Wednesday, May 22nd. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will earn $0.72 per share for the quarter, down from their prior forecast of $0.75. The consensus estimate for Pfizer’s current full-year earnings is $2.38 per share. Zacks Research also issued estimates for Pfizer’s FY2025 earnings at $2.58 EPS.

PFE has been the topic of several other reports. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Morgan Stanley boosted their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $35.86.

Pfizer Stock Performance

NYSE PFE opened at $28.88 on Friday. The firm has a market capitalization of $163.65 billion, a P/E ratio of -481.25, a PEG ratio of 1.13 and a beta of 0.63. The stock has a 50-day simple moving average of $27.27 and a two-hundred day simple moving average of $27.94. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. Pfizer has a fifty-two week low of $25.20 and a fifty-two week high of $40.37.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter last year, the company posted $1.23 earnings per share. The firm’s revenue was down 19.5% compared to the same quarter last year.

Institutional Investors Weigh In On Pfizer

A number of hedge funds have recently modified their holdings of PFE. Ironvine Capital Partners LLC grew its stake in shares of Pfizer by 2.1% in the 1st quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock valued at $470,000 after buying an additional 353 shares during the period. Carr Financial Group Corp grew its position in Pfizer by 3.3% in the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock worth $344,000 after acquiring an additional 355 shares during the period. Advisor OS LLC increased its stake in Pfizer by 1.0% during the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after acquiring an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC raised its position in Pfizer by 3.9% in the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 371 shares during the period. Finally, Cairn Investment Group Inc. raised its position in Pfizer by 5.4% in the third quarter. Cairn Investment Group Inc. now owns 7,323 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 372 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 5.82%. Pfizer’s payout ratio is -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.